Evidence map›Paper›PMID 37875524›Full record

ArticleScientific reports2023

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.

Caroline Bodet-Milin, Cyrille Morvant, Thomas Carlier, Gauthier Frecon, Olivier Tournilhac, Violaine Safar, Françoise Kraeber-Bodere, Steven Le Gouill, Elizabeth Macintyre, Clément Bailly

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Caroline Bodet-MilinUniversité de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France.
Cyrille MorvantUniversité de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France.
Thomas CarlierUniversité de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France.
Gauthier FreconNuclear Medicine Unit, University Hospital, 44093, Nantes, France.
Olivier TournilhacHaematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
Violaine SafarDepartment of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Françoise Kraeber-BodereUniversité de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France.
Steven Le GouillUniversité de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France.
Elizabeth MacintyreOnco-Haematology, Université de Paris, Hôpital and Institut Necker-Enfants Malades, Assistance-Publique-Hôpitaux de Paris, INSERM U1151, Paris, France.
Clément BaillyUniversité de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, France. clement.bailly@chu-nantes.fr.
Nantes Université · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRHospices Civils de Lyon · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognostic value of

Indexed as

Lymphoma, Mantle-CellPositron Emission Tomography Computed TomographyAdultBone MarrowFluorodeoxyglucose F18HumansNeoplasm, ResidualPrognosisRetrospective StudiesFluorodeoxyglucose F18

Identifiers

PMID37875524
PMCPMC10598231
OpenAlexW4387908902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.